Charles River upgraded to Outperform from Market Perform at William Blair

William Blair upgraded Charles River (CRL) to Outperform from Market Perform without a price target The firm believes news updates in recent weeks have begun to ease some of the overhangs on the pharmaceutical outsourcing. These include the Trump administration’s pharma tariffs that gave “extensive leeway” to companies actively building manufacturing capacity in the United States, and President Trump’s press conference with Pfizer to announce a Most Favored Nation framework that was far less punitive than feared, the analyst tells investors in a research note. For Charles River, William Blair says the removal of these overhangs “clears the way for a more immediate and pronounced recovery in preclinical spend.”